[Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells]

Sha Wang1, Yu-bo Chai, Fei Liu

  • 1Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.

Zhonghua Yi Xue Za Zhi
|April 28, 2005
PubMed
Abstract

Insights

Small interfering RNA (siRNA) targeting the bcr-abl chimeric gene effectively reduced its expression in chronic myelogenous leukemia (CML) cells. This inhibition led to decreased proliferation, increased apoptosis, and induced differentiation of CML cells.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Gene Therapy

Context:

  • Chronic myelogenous leukemia (CML) is characterized by the bcr-abl chimeric gene.
  • Targeting this oncogenic driver is a key strategy for CML treatment.
  • RNA interference offers a potential therapeutic approach.

Purpose:

  • To evaluate the efficacy of specific small interfering RNA (siRNA) against the bcr-abl chimeric gene.
  • To investigate the impact of siRNA-mediated gene silencing on CML cell biological characteristics.

Summary:

  • siRNA targeting the bcr-abl chimeric gene significantly reduced its expression in K562 CML cells.
  • This resulted in time-dependent inhibition of cell proliferation, increased apoptosis (43.2%), and induced erythrocytic differentiation (23.5%).
  • Cell cycle analysis revealed a G1-phase arrest, and Western blotting showed down-regulation of Bcl-xL and minimal change in Bax protein.

Impact:

  • Demonstrates the potential of siRNA as a therapeutic agent for CML by targeting the bcr-abl oncogene.
  • Provides insights into the molecular mechanisms by which bcr-abl inhibition affects CML cell fate.
  • Suggests that siRNA-induced apoptosis and differentiation could be a viable strategy for CML management.